Immunethep and i3S Strengthen Strategic Collaboration to Advance Next-Generation Immunotherapies

Immunethep and i3S (Instituto de Investigação e Inovação em Saúde) announced the reinforcement of their strategic collaboration. Through this partnership, Immunethep will continue to leverage i3S’s cutting-edge research facilities and specialized services to accelerate the development of its next-generation therapies targeting infectious diseases, cancer, and inflammatory conditions.

This collaboration, established several years ago, has been significantly reinforced and recognized by new international investment partners, including CARB-X and PACE, who support Immunethep’s mission to deliver transformative solutions in immunotherapy.

"Our longstanding partnership with i3S has been crucial to Immunethep’s scientific advances. With the additional support from CARB-X and PACE, we are even better positioned to translate groundbreaking immunological discoveries into real-world therapies," said Pedro Madureira, CSO of Immunethep.

The strengthened alliance marks an important milestone in Immunethep’s journey to unlock the full potential of the immune system and address significant global health challenges.